Pfizer completes ReViral acquisition

Pfizer (NYSE:PFE) announced today that it completed its previously announced $525 million acquisition of ReViral.

ReViral, a biopharmaceutical company, discovers, develops and commercializes novel antiviral therapeutics designed to target respiratory syncytial virus (RSV). Its portfolio includes the sisunatovir oral inhibitor for blocking the fusion of the RSV virus to the host cell. Sisunatovir has fast track designation from the FDA.

Sisunatovir proved effective in significantly reducing viral load in a phase 2 RSV human challenge study in healthy adults. ReViral currently has a phase 2 clinical development in infants underway, as well as a second program focused on the inhibition of RSV replication, targeting the viral N protein, in phase 1 clinical development.

Pfizer announced in April that it agreed to acquire ReViral for up to $525 million, including upfront and development milestones. The company believes annual revenue for programs related to the transaction could reach or exceed $1.5 billion.

“We are excited to bring ReViral’s promising investigational treatments for RSV into our anti-infective pipeline at Pfizer. This acquisition further demonstrates our commitment to advancing pioneering science – both through our in-house expertise and our work with leading, innovative companies – with the goal of delivering new breakthroughs to patients suffering from serious infectious diseases,” Pfizer CSO and President of Worldwide Research, Development and Medical Dr. Mikael Dolsten said in a news release. “We believe these therapeutic candidates – and the scientific expertise that has advanced their development – will complement our ongoing work to help combat RSV infections, and we look forward to welcoming our new colleagues to further support these endeavors.”